Clinical Trials Logo

Conjunctivitis clinical trials

View clinical trials related to Conjunctivitis.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05641272 Not yet recruiting - Allergic Rhinitis Clinical Trials

Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract

MM09-SLIM
Start date: November 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

Prospective, randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of polymerized and mannan conjugated allergen extract of Dermatophagoides for the treatment of allergic rhinitis/rhinoconjunctivitis with or without asthma. The main objective of the clinical trial is to evaluate the clinical efficacy of the investigational medicinal product, administered sublingually, compared to placebo for the treatment of moderate-severe rhinitis/rhinoconjunctivitis with or without mild to moderate asthma and controlled using the Rhinitis/Rhinoconjunctivitis Combined Symptom and Medication Score (R-CSMS).

NCT ID: NCT05400811 Not yet recruiting - Allergic Asthma Clinical Trials

Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis

Start date: December 2022
Phase: Phase 3
Study type: Interventional

Prospective, randomized, placebo-controlled, multicenter of 3 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate asthma and rhinitis/rhinoconjunctivitis (intermittent or persistent) allergic to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae.

NCT ID: NCT04695795 Not yet recruiting - Clinical trials for Allergic Conjunctivitis

Sea Water in Allergic Conjunctivitis

Start date: February 1, 2021
Phase:
Study type: Observational

Background and purpose: Allergic conjunctivitis has increased alarmingly in recent years. The objectives of the study are: 1) To establish the safety and efficacy of applying eyewashes in spray form as monotherapy on the symptoms and signs of allergic conjunctivitis; 2) To establish the comparative efficacy with other eye drops as antihistamines; 3) To measure the modification of immunoglobulin E (IgE) and matrix metalloproteinase 9 (MMP9) levels in the tears.

NCT ID: NCT04346160 Not yet recruiting - COVID Clinical Trials

A Study to Assess the Virus RNA, and miRNA Levels Related to Viral Infection, and Inflammatory Response in Tears of Patients Affected by COVID-19 Disease

Start date: April 14, 2020
Phase:
Study type: Observational

The aim of this study is to assess the virus RNA, and miRNA levels related to viral infection, and inflammatory response in tears of hospitalized patients with a diagnosis of COVID-19 with and without conjunctivitis and to correlate them with clinical condition. Tears will be collected by using Schirmer Test I, a non invasive painless test which can be performed at the patient's bed. Tears will be collected on the graduated paper strips pulling the lower lid gently downward for 5 minutes. Following, the strip will be placed in a 2.0 mL Eppendorf tube and stored at −80◦C (or - 20°C)

NCT ID: NCT04066998 Not yet recruiting - Atopic Dermatitis Clinical Trials

Cytokine Profile of Conjunctivitis, Performed Through Tears Analysis Among Patients Treated With Dupilumab

CYCLADDE
Start date: December 2019
Phase: N/A
Study type: Interventional

This study aims to assess the cytokine profile of tears in patients suffering from conjunctivitis versus patients without ocular involvement, when treated with Dupilumab

NCT ID: NCT03975374 Not yet recruiting - Clinical trials for Blepharo Conjunctivitis

To Study Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic Suspension

Start date: June 15, 2019
Phase: Early Phase 1
Study type: Interventional

The objective of the study is to compare and describe efficacy and safety of Tobradex ophthalmic suspension versus generic Tobramycin/dexamethasone Suspension in treatment of Blepharoconjuctivitis through clinical parameters

NCT ID: NCT03820154 Not yet recruiting - Allergic Rhinitis Clinical Trials

Diagnostic Equivalence of the Skin Prick Test Tape vs. Conventional Skin PrickTest

SPTTapeD1
Start date: March 1, 2019
Phase: N/A
Study type: Interventional

Testing of a new ready-to-use Tape in comparison to the currently used skin prick test for the diagnosis of allergies. Assessment of clinical equivalence of the SPT Tape for representative common inhalant allergens to conventional SPT in terms of wheal reaction positivity and overall safety. Tests are performed in patients who have a medical history of relevant allergic rhinitis to any of the tested allergens.

NCT ID: NCT03631108 Not yet recruiting - Glaucoma Clinical Trials

Feasibility Study and Preliminary Application Study on Iris OCTA

Start date: October 2018
Phase:
Study type: Observational

All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens. The main outcomes are iris blood flow density and vascular density.

NCT ID: NCT01600365 Not yet recruiting - Conjunctivitis Clinical Trials

Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus

Start date: May 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to study the use of ganciclovir gel 0.3% for treatment of conjunctivitis caused by adenovirus.

NCT ID: NCT01227915 Not yet recruiting - Clinical trials for Acute Bacterial Conjunctivitis

Effectiveness Comparison Between the Drugs TOBRACORT® and TOBRADEX® in Reducing the Signs and Symptoms of Acute Bacterial Conjunctivitis

Start date: February 2011
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate, through clinical parameters, the comparative efficacy between topical Tobracort ® (tobramycin 0.3% dexamethasone + 1% - Chemistry Lab Union) and TOBRADEX ® (tobramycin 0.3% dexamethasone + 1 % - Alcon Lab), using the percentage of improvement (sustained response rate) at the end of treatment.